Results 101 to 110 of about 653,218 (240)

At-a-glance - Pollens, climate and allergies: Quebec initiatives

Health Promotion and Chronic Disease Prevention in Canada, 2019
Pollen allergies are a major source of seasonal allergic rhinitis in North America. This type of rhinitis affects 17% of adults in Quebec, a marked increase in the last 30 years. Ragweed (Ambrosia artemisiifolia L.) pollens are responsible for 50% to 90%
Isabelle Demers, Pierre Gosselin
doaj   +1 more source

Combined intranasal treatment for allergic rhinitis: an option for children under 12 years of age [PDF]

Exploration of Asthma & Allergy
Intranasal treatments combining corticosteroids with antihistamines are a safe and effective alternative for treating moderate to severe seasonal allergic rhinitis in children over 12 years of age and adults.
Alberto Vidal, Pedro Cortez
doaj   +1 more source

Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial

Clinical &Experimental Allergy, EarlyView.
A Phase 1, randomised, placebo‐controlled, dose‐escalation trial was performed with 30 birch pollen allergic subjects treated with DM‐101PX, that contains a recombinant hypoallergenic variant of Bet v 1 formulated with poloxamer 338 thermosensitive hydrogel.
Anna Nilson, Patricia Couroux, Jaana Haka, Silja Halme, Pekka Mattila, R. J. Joost van Neerven, Rolien Pels‐Rijcken, Janneke Ruinemans‐Koerts, Yvonne Schmidt‐Hieltjes, Anne Marie Salapatek, Kati Sallinen, Kristiina Takkinen, Daphne Tsitoura, Dirk‐Jan Opstelten, Juha Rouvinen   +14 more
wiley   +1 more source

Current treatment differences before 2003 and in 2009 in seasonal allergic rhinitis

, 2010
Objective: To evaluate the differences of seasonal allergic rhinitis (SR) treatment options which patients were receiving at admission to our clinic and provided by us later according to Allergic Rhinitis and its Impact on Asthma (ARIA)
KALYONCU, ALİ FUAT, Damadoglu, Ebru, Ozturk, Ayse Bilge, KARAKAYA, GÜL   +3 more
core  

Clinical Effects of Adjunctive Shoseiryuto Therapy in Refractory Eosinophilic Chronic Rhinosinusitis: A Pilot Retrospective Case Series Focusing on Mucus‐Related Symptoms

Traditional &Kampo Medicine, Volume 13, Issue 3, December 2026.
ABSTRACT Aim To evaluate the efficacy and safety of adjunctive shoseiryuto, a traditional Japanese Kampo medicine, in patients with refractory eosinophilic chronic rhinosinusitis (ECRS), with particular attention to mucus‐related symptoms. Methods This retrospective pilot case series was conducted at Osaka Medical and Pharmaceutical University Hospital
Yusuke Kikuoka
wiley   +1 more source

Short‐Course Subcutaneous Immunotherapy With Mannan‐Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Background The mannan‐conjugated birch pollen polymerised allergoid EP‐088_T502 has previously been shown to reduce allergic symptoms and anti‐allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of EP‐088_T502 administered as ...
Esther Raskopf, Sofia Passamera, Ludger Klimek, Oliver Pfaar, Christian Neuhof, Anna Rybachuk, Nadine Katzke, Hacer Sahin, Silke Allekotte, Ralph Mösges, Laura Day, José Luis Subiza, Miguel Casanovas, Mandy Cuevas, Sandra del Pozo   +14 more
wiley   +1 more source

Pooled Analysis for NSS of leukotriene antagonist versus selective H₁ antihistamine for Seasonal allergic rhinitis.

, 2014
Pooled Analysis for NSS of leukotriene antagonist versus selective H1 antihistamine for Seasonal allergic rhinitis.
Jun Wang (5906), Jixiang Zhang (553588), Yu Xu (52257)   +2 more
core   +1 more source

Stapokibart (CM310): A review in seasonal allergic rhinitis

American Journal of Otolaryngology
Stapokibart (CM310), a humanized anti-IL-4Rα monoclonal antibody, blocks IL-4/IL-13 signaling for type 2 inflammatory diseases like seasonal allergic rhinitis (SAR), where standard of care often fails.Assess stapokibart's efficacy on the primary endpoint (reflective Total Nasal Symptom Score, rTNSS) and safety as add-on therapy in SoC-inadequate ...
Ping, Xue, Jing, Yan, Jianwei, Li
openaire   +2 more sources

Single‐cell multi‐omics characterises transcriptional and chromatin accessibility heterogeneity of immune cells in allergic rhinitis

Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.
Key Points 1. SAR and PAR showed distinct immune landscapes. 2. Macro_CCL3 showed phenotype‐specific inflammatory and antigen‐presentation features. 3. CD8_Trm displayed subtype‐associated chromatin accessibility linked to cytotoxicity‐related signatures. 4.
Yisha Wu, Zhihan Xu, Shikai Han, Zhongzhen Liu, Rui Dong, Chuanyu Liu, Jianhua Yin, Jinmei Xue   +7 more
wiley   +1 more source

New aspects of allergic rhinitis treatment

, 2019
Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in different countries. Allergic rhinitis affects negative on the quality of patient’s life and is often associated with asthma.
Olga M. Kolesnikova, Sergei A. Karpishchenko   +1 more
core   +1 more source